Clinical trials: Extensive Disease Small Cell Lung Cancer
Small Cell Lung Cancer
Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
The purpose of this study is to determine if cisplatin and pemetrexed are effective in the treatment of patients with Small Cell Lung Cancer, extended disease.
- Trial name
- NCT00475657
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Spain
- Volunteers
- 5 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT03026166
- Testing
- Ipilimumab, Nivolumab, Rovalpituzumab tesirine
- Where
- 35 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
Extensive-stage Small Cell Lung Cancer
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.
- Trial name
- NCT04562337
- Testing
- SHR1316, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Shandong Cancer Hospital and Institute
Lung Cancer
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer.
- Trial name
- NCT00003726
- Testing
- lepirudin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have…
- Trial name
- NCT00005646
- Testing
- paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00041054
- Testing
- carboplatin, etoposide, exisulind
- Where
- 83 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- Alliance for Clinical Trials in Oncology
SCLC, Extensive Stage
A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients.
- Trial name
- NCT06620796
- Testing
- Arm 1, second-line group
- Volunteers
- 70 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Small Cell Carcinoma of Lung
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally.
- Trial name
- NCT07550842
- Testing
- BL0020, Toripalimab
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Small Cell Lung Cancer (SCLC)
Pembrolizumab in Untreated Extensive SCLC
This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.
- Trial name
- REACTION (NCT02580994)
- Testing
- Pembrolizumab, cis/carboplatin and etoposide
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 125 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
Phase II, single-arm study to assess the safety and efficacy of osimertinib (80 mg, orally, once daily) as first-line therapy in patients with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer…
- Trial name
- FIOL (NCT03804580)
- Testing
- osimertinib
- Where
- 10 sites in Denmark, Lithuania and 2 more
- Volunteers
- 100 people
- Sponsor
- Vestre Viken Hospital Trust
SCLC, Extensive Stage
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
SCLC has a very high degree of malignancy, and 60% to 70% of patients are diagnosed as extensive stage. The median survival of patients with limited-stage disease is about 15-20 months, and the median OS of patients with…
- Trial name
- NCT05299255
- Testing
- Utidelone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Extensive-stage Small-cell Lung Cancer
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.
- Trial name
- NCT06306560
- Testing
- adebrelimab, famitinib, chemotherapy
- Volunteers
- 40 people
- Sponsor
- Harbin Medical University
Small Cell Lung Cancer
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).
- Trial name
- NCT06581380
- Testing
- JK-1201I, Topotecan
- Volunteers
- 394 people
- Sponsor
- JenKem Technology Co., Ltd.
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
This phase I/II trial studies the side effects of bomedemstat and maintenance immunotherapy with atezolizumab and to see how well they work in treating patients with newly diagnosed extensive stage small cell lung cancer.
- Trial name
- NCT05191797
- Testing
- Bomedemstat, Atezolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
ES-SCLC
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection in combination with Chemotherapy and Sequential Thoracic Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT07349225
- Testing
- Iparomlimab and Tuvonralimab Injection, Etoposide, Cisplatin
- Volunteers
- 46 people
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Lung Cancer
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00045162
- Testing
- cisplatin, etoposide, irinotecan hydrochloride
- Where
- 408 sites in United States, Canada
- Volunteers
- 671 people
- Sponsor
- SWOG Cancer Research Network
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Small Cell Lung Cancer
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
This study is a randomized, multi-center clinical trial. Patients are stratified according to performance status (ECOG 0, 1 vs 2) and institution. Patients are randomized to 1 of 2 treatment arms.
- Trial name
- NCT00349492
- Testing
- IP
- Where
- 14 sites in South Korea
- Volunteers
- 372 people
- Sponsor
- Clinical Research Center for Solid Tumor, Korea